Pharmaceutical

AstraZeneca’s Tagrisso gains approval in Canada for NSCLC

AstraZeneca has obtained Health Canada’s Notice of Compliance (NOC) for Tagrisso (osimertinib) to treat NSCLC.

Jul 16, 2024 - 04:00
AstraZeneca’s Tagrisso gains approval in Canada for NSCLC
AstraZeneca has obtained Health Canada’s Notice of Compliance (NOC) for Tagrisso (osimertinib) to treat NSCLC.
Read the original article

Tags:

Previous Article

Mabwell’s 9MW2821 gains FDA fast track status for breast cancer

Next Article

New study reveals more struggling to afford healthcare

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

M&A market performance suffered in Q3 2023

M&A market performance suffered in Q3 2023

Oct 31, 2023

STAT+: Congress’s PBM reforms won’t end America’s drug pricing woes. Here’s what they would do

STAT+: Congress’s PBM reforms won’t end America’s drug ...

Jul 26, 2023

KBI Biopharma and Argonaut form drug manufacturing alliance

KBI Biopharma and Argonaut form drug manufacturing alli...

Jan 17, 2024